Syncona

SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders.

OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.

Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Clade Therapeutics is a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem-cell-based medicines.

Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.

Neogene Therapeutics, Inc. is a biotechnology company based in New York that focuses on the development of T cell therapies to treat cancer. Founded in 2018, the company specializes in creating personalized engineered T-cells that target neo-antigens, which are mutated proteins resulting from DNA alterations in cancer cells. Neogene's innovative platform allows for the isolation of T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies, which are routinely collected from patients. By utilizing advanced DNA sequencing and genetic screening technologies, Neogene can accurately identify and engineer TCRs that enhance the ability of T-cells to detect and eliminate cancer cells. This approach aims to improve treatment outcomes for cancer patients by providing therapies tailored to their unique tumor profiles.

SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders.

OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.

Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing treatments for patients suffering from hormone-resistant breast and prostate cancer, addressing significant unmet clinical needs in this area. Azeria specializes in a pipeline of small molecules that selectively inhibit pioneer factors, which are crucial in the development and progression of these cancers. By targeting these factors, the company aims to provide more effective treatment options for healthcare professionals managing various cancer types, thereby improving outcomes for patients.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.

Orbit Biomedical Limited, a retinal gene therapy company, develops surgical devices and procedures for certain retinal conditions. It also develops a comprehensive, multi-step procedure training process for surgeons and clinical site staff, taking the learner through a series of training modalities during the learning process. The company was incorporated in 2018 and is based in Stevenage, United Kingdom with additional location in Ambler, Pennsylvania.

OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.

SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders.

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company based in London, United Kingdom, focused on developing T cell therapies for various types of cancer, including hematological malignancies and solid tumors. Founded in 2014, the company has an innovative pipeline that includes AUTO1 and AUTO3 targeting B cell malignancies, AUTO2 for multiple myeloma, and AUTO4 and AUTO5 aimed at T cell lymphoma, as well as AUTO6 and AUTO7 for solid tumors. Autolus specializes in T cell programming and manufacturing technology, which it believes will provide a competitive edge in the advancement of next-generation therapies.

Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.

Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.

Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.

Blue Earth Diagnostics Limited is a molecular imaging diagnostics company focused on developing and commercializing novel positron emission tomography (PET) imaging agents for cancer management. The company provides Axumin, an innovative imaging agent for detecting and localizing prostate cancer in men experiencing biochemical recurrence. Additionally, it is advancing a pipeline of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid agents, which are investigational theranostic compounds with potential applications in both imaging and treatment of prostate cancer. Based in Oxford, United Kingdom, with additional offices in Burlington, Massachusetts, and Dublin, Ireland, Blue Earth Diagnostics was incorporated in 2013 and operates as a subsidiary of Bracco Imaging S.p.A. The company aims to address significant unmet medical needs through its advanced imaging solutions, enhancing diagnostic accuracy and treatment decisions for patients with prostate and brain cancers.

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company based in London, United Kingdom, focused on developing T cell therapies for various types of cancer, including hematological malignancies and solid tumors. Founded in 2014, the company has an innovative pipeline that includes AUTO1 and AUTO3 targeting B cell malignancies, AUTO2 for multiple myeloma, and AUTO4 and AUTO5 aimed at T cell lymphoma, as well as AUTO6 and AUTO7 for solid tumors. Autolus specializes in T cell programming and manufacturing technology, which it believes will provide a competitive edge in the advancement of next-generation therapies.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.